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AbstrAct
Background We present a european multicenter study, 
comparing safety data and patient-reported outcomes 
(PrO) from patients undergoing synovial biopsy using 
ultrasound-guided needle biopsy (US-nB), ultrasound-
guided portal and forceps (US-P&F) or arthroscopic-guided 
(ag) procedures.
Objectives to describe safety and PrO data on joint 
indices of pain, stiffness and swelling before and after 
biopsy, procedural discomfort, joint status compared with 
before biopsy and willingness to undergo a second biopsy 
for each technique and compare the three techniques. 
to evaluate the impact on PrO and safety data of 
corticosteroid therapy as part of the biopsy procedure and 
sequential biopsy procedures.
Methods Data were collected on the day of biopsy 
and 7–14 days postprocedure. Joint pain, swelling and 
stiffness indices were recorded as 0–100  mm Visual 
analogue Scale; qualitative outcome variables on five-
point likert scales. groups were compared with linear 
regression, adjusting for disease activity, corticosteroid 
therapy and prebiopsy PrO value and accounting for 
repeated measurements.
Results a total of 524 synovial biopsy procedures 
were documented (402 US-nB, 65 US-P&F and 57 
agSB). there were eight adverse events (1.5%) with no 
difference between biopsy methods (p=0.55). all PrOs 
were improved 2  weeks postprocedure, and there were 
no differences in postbiopsy change in PrOs between 
biopsy methods. corticosteroid administration, whether 
intramuscular (n=62) or intra-articular (n=38), did 
not result in more adverse events (p=0.81) and was 
associated with reduction in postbiopsy swelling (p<0.01). 
Sequential biopsy procedures (n=103 patients) did not 
result in more adverse events (p=0.61) or worsening in 
PrO data.
Conclusion Overall, our results do not suggest a 
significant difference in safety or patient tolerability 
between US-nB, US-P&F and agSB sampling. Further, 
Key messages
What is already known about this subject?
 ► arthroscopic-guided synovial biopsy, ultra-
sound-guided needle biopsy and ultrasound-guided 
portal and forceps methods has been shown to be a 
safe and well-tolerated procedures, although with-
out comparison of patient-reported outcomes and 
safety between the methods.
What does this study add?
 ► this is the largest comparative study evaluating 
the tolerability and safety of ultrasound-guided and 
arthroscopic biopsy techniques and we found no 
significant difference between ultrasound-guided 
needle biopsy, ultrasound-guided portal and forceps 
or the arthroscopic-guided synovial biopsy methods.
 ► Further, corticosteroid therapy as part of the biopsy 
procedure and sequential biopsies is safe and well 
tolerated in patients.
How might this impact on clinical practice?
 ► From a safety and patient perspective, all three sy-
novial biopsy methods can be used in both trials and 
clinical practice.
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Figure 1 (A) The ultrasound-guided needle biopsy (US-NB) procedure of wrist, in outpatient clinic using local anaesthesia. 
In the lower right corner example of biopsy needle. (B) Image of ultrasound guidance during US-NB procedure. (C) and (D) 
Portal and forceps technique: using rigid and flexible forceps through a disposable portal under local anaesthesia, (E) Synovial 
sampling within the knee joint under ultrasound control. (F) Arthroscopy of wrist, in operating theatre, patient under general 
anaesthesia. In lower corner examples of biopsy equipment. (G) Video guidance used to visualise synovium during arthroscopy.
corticosteroid therapy as part of the biopsy procedure and sequential 
biopsies is safe and well tolerated in patients.
InTROduCTIOn
Synovial tissue analysis could provide a step change towards 
personalising diagnosis, disease stratification and treatment 
selection of patients with inflammatory arthritis.1 2Arthro-
scopic-guided synovial biopsy (AGSB) is to date regarded 
as the ‘gold standard’ for synovial tissue acquisition due 
to extensive validation examining synovial biopsy perfor-
mance and patient tolerability and safety.3 4 However, 
the technical skills and equipment required generally 
restrict the use of arthroscopy for research purposes to 
targeting large joints and within academic centres in 
rheumatology practice.2 4–6 By contrast, minimally invasive 
ultrasound-guided needle biopsy (US-NB) or portal and 
forceps (US-P&F) are becoming widely adopted.7–9 These 
approaches permit access to synovial tissue in a wider range 
of joints, are technically simple, relatively inexpensive to 
perform and have a generally good safety record.5 7 10 11 
However, the wide scale adoption of US-guided techniques 
in clinical trials and in routine care requires further studies 
evaluating patient safety and tolerability of the techniques, 
particularly compared with the gold standard of arthros-
copy.4
The aim of this multicenter retrospective cohort study 
of patients with inflammatory arthritis undergoing 
US-NB, US-P&F and AGSB was to evaluate whether there 
were significant differences in safety and tolerability 
between the techniques.
PaTIenTs and MeTHOds
Participating centers
The study protocol was presented at the European Syno-
vitis Study Group European League Against Rheumatism 
(EULAR) meeting in June 2017. Centres with consecutive 
cohorts of patients with inflammatory arthritis undergoing 
US-NB or US-P&F and AGSB procedures with patient-re-
ported outcome (PRO) data and safety data were invited 
to participate in the study. Academic rheumatology centres 
with suitable cohorts of patients included in the study were: 
Barts and the London School of Medicine and Dentistry 
(UK) (data from the multicenter studies Stratification of 
Biologic Therapies for Rheumatoid Arthritis by Patho-
biology (STRAP) and Response—Resistance to Ritux-
imab vs Tocilizumab in Rheumatoid Arthritis (R4RA) 
trials), Odense University Hospital (Denmark) (data 
from the SynRA study), Birmingham (UK) (data from the 
Birmingham Early Arthritis Cohort (BEACON)), Brussels 
(Belgium) and Lisbon Academic Medical Centre (data 
from mini-arthroscopy cohort, Portugal).
Biopsy procedures
US-guided needle biopsy
US-NB procedures (figure 1A) were performed in a clean 
procedure room or operating theatre, on both large 
joints and small joints, as previously described.7 Briefly, 
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local anaesthetic was injected into the soft tissue up to the 
joint capsule and into the joint space and a Quick-Core 
biopsy needle (16/14-gauge; Cook Medical) was then 
guided by ultrasound and placed within the joint capsule 
(figure 1B) to retrieve synovium.
US-guided portal and forceps
US-P&F procedures (figure 1C–E) were performed in 
a clean procedure room on large joints (knee, ankle 
and wrist).8 9 Briefly, local anaesthetic was injected into 
the soft tissue up to the joint capsule and into the joint 
space. A single 7 Fr disposable portal was placed using 
Seldinger technique under ultrasound guidance, within 
the joint capsule. Hereafter, synovial biopsies were 
obtained, through the portal, using rigid 2.2 mm (Hart-
mann Herzfeld, Medicon, Germany) and flexible 2.2 mm 
(Tontarra, Germany) forceps (figure 1C–E).
arthroscopic-guided synovial biopsy
AGSB procedures (figure 1F) were performed in 
an operating theatre setting or a clean procedure 
room, on both small and large joints, as previously 
described.5 12 13 Arthroscopy was performed using local, 
regional or general anaesthesia.
Briefly, for the wrist joint, patients underwent general 
anaesthesia and up to 5 kg of traction across the wrist. 
Two standard arthroscopic portals were inserted into the 
radiocarpal joint, one for arthroscopic visualisation and 
the other for instrumentation. Synovial biopsies were 
obtained under direct visual inspection (figure 1G), 
using a Quick-Core biopsy needle (16/14-gauge; Cook 
Medical) (figure 1F) a standard wrist arthroscopy punch 
was also used (figure 1F, lower right corner insert). For 
the knee joint, standardised procedures for synovial 
tissue collection in clinical trials, under local anaesthesia, 
were followed as previously described.13 Arthroscopies 
were performed with (‘wet’) and without (‘dry’) flow of 
saline through the joint during the procedure.
Patients
Patient characteristics including age, gender, diagnosis, 
disease duration, joint biopsied, C-reactive protein 
(CRP), erythrocyte sedimentation rate (ESR) and rheu-
matological medication (conventional synthetic (cs) 
disease-modifying antirheumatic drugs (csDMARD), 
biological DMARDs (bDMARDs), corticosteroid), disease 
activity score in 28 joints with CRP or ESR (DAS28CRP or 
DAS28ESR), use of intramuscular (IM) or intra-articular 
(IA) corticosteroids immediately following biopsy were 
collected.
PRO data
Prebiopsy (day of biopsy) and postbiopsy (7–14 days post-
procedure) pain, stiffness and swelling (Visual Analogue 
Scale (VAS) from 0 to 100 mm) were collected for each 
biopsy procedure. Further, PROs if available, on the 
degree of discomfort during the procedure, prebiopsy 
and postbiopsy evaluation of worsening/improvement 
of joint symptoms and the willingness of the patient to 
undergo another biopsy were also collected using five-
point Likert scales.
safety data
All registered adverse events (no time restriction) 
between time of biopsy to November 2017 were collected, 
including, but not limited to, data on presyncope, 
syncope, tenosynovitis, joint infection, deep vein throm-
bosis, nerve or tendon damage or haemarthrosis.
statistical analysis
Categorical variables on patient characteristics were 
presented as numbers and percentages, and continuous 
variables as means with SD. Between-group PRO data 
comparisons were performed using both unadjusted and 
adjusted linear regression, adjusting for biopsy method, 
disease activity, IM or IA corticosteroid use during biopsy 
procedure and the prebiopsy PRO value.14 Robust cluster 
estimation was used in the linear regressions to account 
for minor deviations from the model assumptions on 
normality and to account for repeated measurements 
of some patients. Differences in answers between biopsy 
methods in the questions measured on Likert scales were 
analysed by multinomial logistic regression using robust 
cluster estimation and adjusting for disease activity and 
IM or IA corticosteroid used during biopsy procedure. In 
the analysis of discomfort during procedure, AGSB proce-
dures performed in general anaesthesia were excluded. 
Tests for interaction between biopsy technique and use 
of peri-biopsy IM or IA corticosteroid were conducted in 
relation to the PRO outcomes on discomfort and rebi-
opsy. Comparison of PRO data in the cohort of patients 
with repeated biopsies was performed using linear regres-
sion with robust cluster estimation, both unadjusted and 
adjusting for disease activity, corticosteroid use during 
biopsy procedure and in post-PRO values, the prebiopsy 
PRO data value. P values <0.05 were taken as statistically 
significant. Data were analysed on Stata V.15.
ResulTs
Patients and procedures
Data from a total of 524 synovial biopsy procedures were 
included from 421 patients. Of these, 43% (228/524) of 
the procedures were performed as part of the multicentre 
R4RA (14 centres) and STRAP (nine centres) trials led by 
Barts and the London, while the remaining procedures 
were included from Brussels, n=122 (23%), Odense, 
n=98 (19%), Birmingham, n=56 (11%) and Lisbon, n=20 
(4%) centres. A total of 318 patients (75.5%) underwent 
one synovial biopsy and 103 (24.5%) a repeat biopsy. 
Overall, 77% (402/524) of procedures were performed 
using US-NB, 12% (65/524) were performed using 
US-P&F and 11% (57/524) were performed using AGSB. 
For details on distribution of biopsy methods between 
centres, please see online supplementary table 1A and B. 
In the arthroscopy group, 77% (44/57) were performed 
using local anaesthesia and 23% (13/57) under general 
anaesthesia. In the US-NB group, biopsies were primarily 
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Table 1 Patient characteristics 
US-NB US-P&F AGSB Total P values Missing (%)
Biopsy procedures, n (%) 402 (76.7) 65 (12.4) 57 (10.9) 524 (100.0)
Age, mean (SD) 55.93 (13.79) 52.43 (12.07) 52.30 (17.00) 55.12 (14.00) 0.05 1.9
Gender, n (%) 
  Female, n (%) 285 (72.5) 35 (53.8) 38 (70.4) 358 (69.9) 0.01 2.3
Diagnosis, n (%) 
  Rheumatoid arthritis, n (%) 360 (89.6) 42 (64.6) 27 (47.4) 429 (81.9)
  Undifferentiated arthritis, n (%) 20 (5.0) 8 (12.3) 2 (3.5) 30 (5.7)
  Spondyloarthritis, n (%) 7 (1.7) 0 (0.0) 2 (3.5) 9 (1.7)
  Psoriatic arthritis, n (%) 7 (1.7) 9 (13.8) 2 (3.5) 18 (3.4)
  Degenerative, n (%) 0 (0.0) 0 (0.0) 13 (22.8) 13 (2.5)
  Other, n (%) 8 (2.0) 6 (9.2) 11 (19.3) 25 (4.8) <0.01 0
  Disease duration (years) 8.21 (9.74) 0.53 (1.35) 9.09 (9.40) 7.25 (9.42) <0.01 8.5
Time from diagnosis to biopsy 
  Under 1 month, n (%) 53 (13.2) 40 (61.5) 1 (1.8) 94 (17.9)
  One to 12 months, n (%) 42 (10.4) 15 (23.1) 11 (19.3) 68 (13.0)
  Over 1 year, n (%) 307 (76.4) 10 (15.4) 45 (78.9) 362 (69.1) <0.01 0
Joint biopsied 
  Wrist, n (%) 277 (69.3) 1 (1.5) 18 (31.6) 296 (56.7)
  Knee, n (%) 34 (8.5) 56 (86.2) 39 (68.4) 129 (24.7)
  MCP, n (%) 74 (18.5) 0 (0.0) 0 (0.0) 74 (14.2)
  Ankle, n (%) 2 (0.5) 8 (12.3) 0 (0.0) 10 (1.9)
  Elbow, n (%) 8 (2.0) 0 (0.0) 0 (0.0) 8 (1.5)
  MTP, n (%) 5 (1.3) 0 (0.0) 0 (0.0) 5 (1.0) <0.01 0.4
Disease activity score (DAS28-CRP/ESR), n (%) 
  EULAR remission 28 (10.4) 4 (6.3) 2 (5.7) 34 (9.3)
  EULAR low disease activity 14 (5.2) 7 (11.1) 7 (20.0) 28 (7.6)
  EULAR moderate disease activity 98 (36.4) 31 (49.2) 18 (51.4) 147 (40.1)
  EULAR high disease activity 129 (48.0) 21 (33.3) 8 (22.9) 158 (43.1) <0.01 29
Treatment 
  Naive 131 (35.2) 58 (89.2) 25 (51.0) 214 (44.0) <0.01 7.2
  csDMARDs 218 (58.6) 7 (10.8) 23 (46.9) 248 (51.0) <0.01 7.2
  Oral corticosteroid 64 (15.9) 2 (3.1) 13 (22.8) 79 (15.1) <0.01 7.2
  bDMARDs 53 (14.2) 1 (1.5) 1 (2.0) 55 (11.3) <0.01 7.2
IM or IA corticosteroid at biopsy procedure 
  IM corticosteroid at biopsy, n (%) 55 (13.7) 3 (4.6) 4 (7.0) 62 (11.8)
  IA corticosteroid at biopsy, n (%) 26 (6.5) 0 (0.0) 12 (21.1) 38 (7.3) <0.01 0
AGSB, arthroscopic-guided synovial biopsy; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drugs; ESR, erythrocyte 
sedimentation rate; EULAR, European League Against Rheumatism; IA, intra-articular; IM, intramuscular; MCP, metacarpophalangeal; 
MTP, metatarsophalangeal; US-NB; ultrasound-guided needle biopsy; US-P&F, ultrasound-guided portal and forceps.
from the wrist (69%) and, as the only method, also from 
small joints as metacarpophalangeal (MCP) (18%) and 
metatarsophalangeal (MTP) (1%) joints. In the US-P&F 
and arthroscopy groups, the primary joint biopsied was 
the knee (86% and 68%, respectively). Characteristics of 
patients at the time of biopsy are shown in table 1
When patients were categorised according to biopsy 
technique, significant differences in gender, diagnosis, 
disease duration, time from diagnosis to biopsy, joint 
biopsied and EULAR disease activity criteria between 
groups were demonstrated, reflecting a diversity in the 
patients with inflammatory arthritis recruited at each 
centre. In addition, significant differences in rheumato-
logical medication were found between biopsy groups: 
44% (214/524) of patients were treatment naive with 
the greatest proportion in the US-P&F group (89.2% 
(58/65), p<0.01). In total, 51%, (248/524) of patients 
were being treated with one or more csDMARD. The 
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prevalence of bDMARDs was highest in the US-NB group 
(14% (53/402), p<0.01), while use of steroid during 
biopsy procedure (IM or IA) was lowest in the US-P&F 
group (3% (3/63), p<0.01). Detailed information on 
csDMARD and bDMARD therapy is shown in online 
supplementary table 2.
Tolerability of biopsy procedures
In order to determine whether there were significant 
differences in tolerability of the procedures between the 
three biopsy techniques, we next evaluated differences in 
pain, stiffness and swelling before and after the biopsy 
procedure. Although we found significantly higher preb-
iopsy levels of pain and swelling within the arthroscopic 
group (p<0.01), we found no significant differences in 
postbiopsy pain, swelling and stiffness levels. Further, we 
found that the changes in pain, stiffness and swelling 
from baseline were not significantly different between 
biopsy techniques (online supplementary table 3).
For all patients biopsied, irrespective of method and for 
each method individually, we found that pain, swelling 
and stiffness all decreased significantly after the proce-
dure (figure 2A). These results indicate that all biopsy 
techniques evaluated were generally well tolerated, often 
with significant reduction in pain, swelling and stiffness 
of joints following biopsy.
Among patients undergoing procedures under local 
anaesthesia, we found that a high proportion of patients 
undergoing each biopsy technique experienced absent 
or only mild discomfort (US-NB 72% (196/271), US-P&F 
71% (46/65), AGSB 62% (24/39)), we found no signif-
icant difference in outcomes in the adjusted analysis 
between methods (p=0.72) (figure 2B).
In the patients undergoing US-NB and US-P&F, we 
were also able to evaluate answers to the question ‘How 
does joint feel compared with before biopsy’ (figure 2C). 
In both the US-NB and US-P&F group, 87% (75/86) and 
99% (54/55), respectively, of the patients answered that 
the joint felt the same or better. When comparing the 
answers in adjusted analysis, the US-P&F group scored 
better compared with the US-NB group (p<0.01).
Finally, we evaluated differences regarding willingness 
to undergo a repeat biopsy (figure 2D). In all groups, the 
majority of patients were somewhat or very likely to agree 
to another biopsy (US-NB 57% (98/175), US-P&F 85% 
(47/55), AGSB 64% (23/31)). Adjusted analysis demon-
strated that patients undergoing both US-P&F and AGSB 
were more willing than those undergoing US-NB to 
undergo a repeat procedure (US-P&F vs US-NB: p<0.01 
and AGSB vs US-NB: p<0.01), while there was no signifi-
cant difference between US-P&F and AGSB (p=0.85).
Outcomes in patients undergoing repeated biopsy procedures
In the 103 patients who had undergone two biopsy proce-
dures, we evaluated differences in VAS scores for preproc-
edure and postprocedure pain, stiffness and swelling and 
differences in willingness to undergo a repeat biopsy. Of 
the 103 patients, the majority (84.5%, (87/103)) had 
undergone US-NB and 11% (11/103) US-P&F and 5% 
(5/103) AGSB (table 2).
The majority of repeat biopsies were performed in 
patients with rheumatoid arthritis (97.1% (100/103)) 
who were biopsied from the wrist (68% (70/103)). 
Disease activity was significantly higher on first biopsy 
compared with second (96.6% moderate or high disease 
activity at biopsy 1 vs 44.5% at second biopsy, p<0.01), 
with 44% in remission at the second biopsy with 0% at 
the first biopsy (table 2).
Comparing PRO data between the first and second 
biopsy, adjusting for potential confounders, we demon-
strated lower pre-pain (p<0.01), pre-stiffness (p<0.01) 
and pre-swelling and post-swelling (both p<0.01) in 
patients undergoing a second biopsy, while other PRO 
data were not significantly different. No statistically 
significant differences were found in delta PRO values 
between first and second biopsy (table 2).
When evaluating differences in whether patients were 
willing to undergo a repeat biopsy between first and 
second biopsy, we saw no differences in whether they 
were somewhat likely or very likely to undergo a repeat 
biopsy (first biopsy 72% (41/57), second biopsy 59% 
(34/58)). Notably, there was no significant decline in 
willingness between first and second biopsy (p=0.51). 
Further, there were no significant differences in adjusted 
analyses of VAS data (pain, stiffness, swelling or delta 
values) between biopsy techniques in patients under-
going repeated biopsies (data not shown).
The effect of peri-biopsy corticosteroid therapy on PRO data
In order to determine whether the administration of 
peri-biopsy corticosteroids influenced patient tolerability, 
we evaluated whether significant differences in pre-pain 
and post-pain, stiffness and swelling for each biopsy tech-
nique differed according to administration of IM or IA 
corticosteroid.
First, we evaluated all procedures (n=424) where treat-
ment with peri-biopsy corticosteroid was not used and 
in adjusted analysis found significant decreases in pain, 
stiffness and swelling after biopsy in the US-NB (n=321), 
US-P&F (n=62) and AGSB procedures (n=16) (table 3).
In the cohort of patients treated with peri-biopsy corti-
costeroids (n=100) (US-NB (n=81), US-P&F (n=3), AGSB 
(n=16)), we demonstrated a significant decrease in all 
three PRO parameters for US-NB and both pain and 
stiffness for arthroscopic biopsy (table 3). In the US-P&F 
group, there was insufficient data (only three proce-
dures) to demonstrate a possible decrease in the three 
PRO parameters.
When all procedures were combined and adjusted for 
biopsy method, disease activity and pre-PRO value, the 
use of corticosteroid significantly reduced post-swelling 
VAS data (p<0.01), but not postprocedure pain (p=0.15) 
or stiffness (p=0.13).
We found no interaction between biopsy technique and 
use of peri-biopsy IM or IA corticosteroid in relation to 
the discomfort (p=0.33) or rebiopsy questions (p=0.95). 
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Figure 2 (A) Graphs of patient reported data on Visual Analogue Scale for (a) ultrasound-guided needle biopsy (US-NB), 
(b) ultrasound-guided portal and forceps (US-P&F) and (c) arthroscopic-guided synovial biopsy (AGSB) and (d) all methods 
combined are presented. *P<0.05. (B) Answer to question on discomfort during procedure. The AGSB procedures using 
general anaesthesia not included. (C) Answer to question on how the joint feels during compared with before biopsy. 
Arthroscopy not applicable due to small amount of data. (D) Answer to question on whether the patient would participate in 
another biopsy.
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Table 2 Repeated biopsy procedures
Baseline Repeat biopsy P values P values* Missing (%)
n 103 103
Months between biopsies† 5.37 (5.50)
Biopsy method 
  US-NB, n (%) 87 (84.5) 88 (85.4)
  US-P&F, n (%) 11 (10.7) 11 (10.7)
  AGSB, n (%) 5 (4.9) 4 (3.9) 0.94
Diagnosis 
  RA, n (%) 100 (97.1) 100 (97.1)
  UA, n (%) 1 (1.0) 1 (1.0)
  PsA, n (%) 2 (1.9) 2 (1.9) 1.00
Joint biopsied 
  Elbow, n (%) 2 (1.9) 2 (1.9)
  Wrist, n (%) 70 (68.0) 70 (68.0)
  MCP, n (%) 8 (7.8) 8 (7.8)
  Knee, n (%) 20 (19.4) 20 (19.4)
  Ankle, n (%) 2 (1.9) 2 (1.9)
  MTP, n (%) 1 (1.0) 1 (1.0) 1.00 0.4
EULAR disease activity 
  Remission, n (%) 0 (0.0) 28 (43.8)
  Low activity, n (%) 3 (3.4) 4 (6.3)
  Moderate activity, n (%) 42 (47.7) 21 (32.8)
  High activity, n (%) 43 (48.9) 11 (17.2) <0.01 29.9
Patient-reported outcome measures 
  Pre-pain, mean (SD) 54.96 (28.01) 32.90 (26.01) <0.01 <0.01 2.5
  Post-pain, mean (SD) 39.30 (29.29) 27.05 (24.12) <0.01 0.6 7.5
  Pre-swelling, mean (SD) 50.46 (29.56) 28.70 (25.32) <0.01 <0.01 5.3
  Post-swelling, mean (SD) 34.94 (30.55) 20.14 (22.79) <0.01 <0.01 9.5
  Pre-stiffness, mean (SD) 57.16 (27.62) 31.11 (24.27) <0.01 <0.01 5.3
  Post-stiffness, mean (SD) 35.60 (29.55) 22.54 (23.84) <0.01 0.52 9.3
  Delta pain, mean (SD) −15.23 (29.93) −5.53 (21.13) 0.01 0.62 7.6
  Delta swelling, mean (SD) −15.04 (31.87) −7.67 (26.41) 0.06 0.70 9.9
  Delta stiffness, mean (SD) −21.30 (32.70) −7.90 (21.58) <0.01 0.52 9.7
Participate in another biopsy? 
  Very unlikely, n (%) 6 (10.5) 5 (8.6)
  Somewhat unlikely, n (%) 2 (3.5) 3 (5.2)
  Not sure, n (%) 8 (14.0) 16 (27.6)
  Somewhat likely, n (%) 8 (14.0) 8 (13.8)
  Very likely, n (%) 33 (57.9) 26 (44.8) 0.25 0.51 50.2
*P values adjusted for baseline or follow-up biopsy, disease activity, intra-articular or intramuscular corticosteroid injection during biopsy. 
P-values on post and delta values were also adjusted for prevalue.
†Mean for all in group.
EULAR, European League Against Rheumatism; GSB, arthroscopic-guided synovial biopsy; MCP, metacarpophalangeal; MTP, 
metatarsophalangeal; PsA, psoriatic arthritis; RA, rheumatoid arthritis; UA, undifferentiated arthritis; US-NB, ultrasound-guided needle 
biopsy; US-P&F, ultrasound-guided portal and forceps.
Analysis was not possible for ‘How joints feel compared 
with before biopsy’ in the arthroscopy group due to low 
numbers.
safety data
We next collected data on all adverse events per biopsy 
technique and evaluated whether significant differences 
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Table 3 Effect of peri-biopsy corticosteroid therapy
Prebiopsy Postbiopsy P values* P values†
Without IM or IA steroid
US-NB (n=321) 
  Pain (mean (SD)) 53.6 (28.9) 41.4 (30.4) <0.001 <0.001
  Stiffness (mean (SD)) 51.9 (30.4) 39.4 (30.8) <0.001 <0.001
  Swelling (mean (SD)) 50.9 (30.9) 38.2 (30.1) <0.001 <0.001
US-P&F (n=62) 
  Pain (mean (SD)) 43.7 (32.5) 31.6 (27.2) 0.003 0.005
  Stiffness (mean (SD)) 45.5 (33.7) 33.4 (27.6) 0.003 0.006
  Swelling (mean (SD)) 39.3 (32.7) 30.7 (26.4) 0.021 0.029
AGSB (n=41) 
  Pain (mean (SD)) 62.3 (23.5) 49.3 (22.4) 0.017 0.001
  Stiffness (mean (SD)) 45.4 (31.5) 38 (26.6) 0.296 0.001
  Swelling (mean (SD)) 49.6 (30.9) 41.7 (28.2) 0.198 <0.001
With IM or IA steroid 
US-NB (n=81)
  Pain (mean (SD)) 46.3 (29.4) 31.8 (26.9) 0.001 <0.001
  Stiffness (mean (SD)) 49.8 (30.1) 31.2 (28.2) <0.001 0.001
  Swelling (mean (SD)) 47.8 (29.9) 27.3 (27.7) <0.001 <0.001
US-P&F (n=3) 
  Pain (mean (SD)) 84.7 (7.2) 49.3 (33.5) 0.173 0.279
  Stiffness (mean (SD)) 83.7 (8.1) 40.7 (42.4) 0.192 0.304
  Swelling (mean (SD)) 76 (21.3) 42 (36) 0.189 0.300
AGSB (n=16) 
  Pain (mean (SD)) 62.9 (26) 28.9 (16.1) <0.001 <0.001
  Stiffness (mean (SD)) 57.5 (25.2) 31.8 (20.4) <0.001 <0.001
  Swelling (mean (SD)) 61.9 (23.0) 24.2 (14.2) <0.001 <0.001
*P value by unadjusted cluster linear regression.
†Here adjusted for disease activity and pre-PRO value.
AGSB, arthroscopic-guided synovial biopsy; IA, intra-articular; IM, intramuscular; US-NB, ultrasound-guided needle biopsy; US-P&F, 
ultrasound-guided portal and forceps.
in rates of complications existed between procedures. 
Safety data was available on all procedures. Biopsy proce-
dures were performed in the time interval between 
September 2012 and November 2017, with follow-up data 
available for a mean of 16 months (US-NB 15 months, 
US-P&F 12 months, AGSB 23 months).
Overall, there were n=8 (1.5%) adverse events. 
Although all complications were reported within the 
US-guided procedure group, overall there was no differ-
ence in number of adverse events between the biopsy 
methods (p=0.55) (table 4). The most common compli-
cation reported was postprocedure sensory disturbance 
(n=4), all within US-NB procedures.
Further, in the 100 procedures in which IM (n=62) or 
IA (n=38) corticosteroid therapy was administered we 
also evaluated the effect on adverse events. We found 
no higher risk of adverse events in the group receiving 
corticosteroid (p=0.81). Neither was there a higher risk 
in patients receiving bDMARDs at the time of biopsy 
(n=55, p=0.63). In the patients undergoing two biopsies 
there was no higher risk of adverse events when under-
going the second biopsy procedure compared with first 
(p=0.61).
dIsCussIOn
We herein present a multicentre study across European 
academic rheumatology centres evaluating PRO and 
safety data from 524 synovial biopsy procedures where 
either US-NB, US-P&F or AGSB techniques where used. 
Our results demonstrate a number of important findings. 
First, all three synovial biopsy techniques were safe and 
well tolerated with no significant differences demon-
strated between techniques in PROs or adverse events 
demonstrated. Second, patients are broadly willing to 
undergo repeat ultrasound-guided procedures, and this 
willingness does not decrease when repeats occur. Third, 
our results suggest that peri-biopsy administration of IM 
 o
n
 18 D
ecem
ber 2018 by guest. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2018-000799 on 26 O
ctober 2018. Downloaded from
 
9Just Sa, et al. RMD Open 2018;4:e000799. doi:10.1136/rmdopen-2018-000799
Inflammatory arthritis
Table 4 Safety data
Safety US-NB US-P&F AGSB Total P values
Biopsy procedures, n (%) 402 (76.7) 65 (12.4) 57 (10.9) 524 (100.0)
Syncope or presyncope, n (%) 2 (0.8) 0 (0.0) 0 (0.0) 2 (0.4)
Tenosynovitis 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.2)
Neurological disturbance*, n (%) 4 (1.0) 0 (0.0) 0 (0.0) 4 (1.0)
Tendon damage, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Haemarthrosis, n (%) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.2)
Deep vein thrombosis 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Joint infection 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Total adverse events 8 0 0 8 0.55†
*Sensory impairment following biopsy, no motor involvement.
†Test for difference in total number of adverse events in each group, by Fishers exact.
AGSB, arthroscopic-guided synovial biopsy; US-NB, ultrasound-guided needle biopsy; US-P&F, ultrasound-guided portal and forceps.
or IA corticosteroid is safe and can improve tolerability of 
the procedure. Finally, our results suggest no new safety 
or tolerability issues in a large cohort of patients under-
going sequential synovial biopsy using any of the three 
techniques.
To our knowledge, this is the largest comparative study 
evaluating the tolerability and safety of US-guided and 
arthroscopic biopsy techniques. Such an evaluation is 
important as the application of US-guided techniques to 
sample synovial tissue has become increasingly common, 
driven by a minimally invasive approach with no require-
ment for operating theatre time and studies supporting 
the quality of synovial tissue obtained using these proce-
dures.4 7 15 However, the previously held perception that 
minimally invasive US-guided procedures are better 
tolerated than arthroscopy is not supported by our data, 
suggesting that patients are able to tolerate all proce-
dures with minimal discomfort or postprocedure pain.4 
It is important to note that for all three biopsy tech-
niques, the majority of patients would agree to a subse-
quent biopsy. Furthermore, despite a significant fall in 
disease activity measures in patients prior to undergoing 
a second biopsy, with a consequent reduction in the 
inflamed synovial tissue mass, available to sample, there 
were no significant increases in PROs including postpro-
cedure pain, swelling or stiffness.
Further adding to the methods tolerability, in patients 
not receiving IM or IA steroid treatment, there was an 
overall improvement in postbiopsy pain, swelling and 
stiffness (table 3). This effect could be driven by other 
factors such as start or change of treatment, patient reas-
surance, good experience with procedure and treatment 
staff and the effect of more attention given to patients in 
clinical studies. The focus of this study was that there was 
no worsening in PRO data.
When considering the integration of synovial biopsy 
into clinical trials recruiting patients with highly active 
disease, peri-biopsy administration of corticosteroids 
is important for subsequent swift and effective control 
of synovitis. However, it is uncertain whether this is 
associated with an increased risk of adverse events. Our 
data suggests that clinicians can safely administer corti-
costeroids following synovial sampling with any of the 
three techniques examined and that corticosteroids 
reduced patient reported postprocedure swelling. It is 
also important to note that our results do not suggest an 
increased risk of adverse events in patients treated with 
biologics undergoing synovial biopsy.
The results on safety presented here are in line with 
previous studies. AGSB has been shown to be a safe and 
well-tolerated procedure with a low rate of complica-
tions.3 5 16 Both US-NB and US-P&F methods have previ-
ously been found reliable, safe and tolerable in both 
small and large joints in smaller cohorts.7–9
The comparative examination in this study of 524 
synovial biopsy procedures remains the largest reported 
cohort to date, and the inclusion of patients with both 
early and established disease and with a wide variation in 
disease activity suggests the results may be generalisable. 
The study has limitations including the heterogenous 
characteristics of the patient cohorts, possible difference 
in number of retrieved biopsies per procedure, the rela-
tively small number of AGSB procedures available for 
comparison, the number of contributing biopsy centres 
and the retrospective nature of the study. Nor were we 
able to take into account the ‘operator’ effect on biopsy 
outcomes and the procedure allocation. The tolerability 
and the PRO measures could also have been influenced 
by the fact that the majority of these patients have been 
included in large interventional treatment studies.
Further, although no new safety signals were identified 
in this study, the relative infrequency of adverse events 
makes ongoing evaluation of larger cohorts important.
Future efforts should focus on PRO measures driven 
and developed by patients undergoing the procedure and 
applied to prospective patient cohorts.17 The continued 
study of PRO data and development of the current instru-
ment is essential in order to meet the needs of the diverse 
patient group that will undergo biopsy as the method is 
implemented in further studies.
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